The FDA has granted priority review to the supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results